The utility of ISCOMATRIX™ adjuvant for dose reduction of antigen for vaccines requiring antibody responses

Boyle, Jeff; Eastman, Donna J.; Millar, Christine; Camuglia, Sarina; Cox, John C.; Pearse, Martin J.; Good, Jeremy; Drane, Debbie

doi:10.1016/j.vaccine.2006.12.018

Cited by 43 publications

(24 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A significant dose-sparing effect was reported in a mouse model for influenza, where similar Ab titres to those induced with split MEM71 influenza virus were achieved with ISCOMATRIX vaccine containing 100-fold less antigen (Sanders et al, 2009). Enhanced immunogenicity at a low dose of antigens was also observed using recombinant gp120 in guinea pigs (Boyle et al, 2007).…”

Section: Dose-sparing Benefits Of Iscomatrix Vaccinesmentioning

confidence: 60%

ISCOMATRIX: a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases

Morelli

Becher

Koernig

et al. 2012

Journal of Medical Microbiology

Self Cite

116

View full text Add to dashboard Cite

The ISCOMATRIX adjuvant has antigen delivery and presentation properties as well as immunomodulatory capabilities, which combine to provide enhanced and accelerated immune responses. The responses are broad, including a range of subclasses of antibodies as well as CD4+ and CD8 + T-cells. A range of ISCOMATRIX vaccines (ISCOMATRIX adjuvant combined with antigen) have now been tested in clinical trials and have been shown to be generally safe and well tolerated as well as immunogenic, generating both antibody (Ab) and T-cell responses. The mechanisms by which ISCOMATRIX adjuvant facilitates its immune effects are the scope of significant study and indicate that ISCOMATRIX adjuvant (i) rapidly traffics antigen into the cytosol of multiple dendritic cell subsets, (ii) induces the induction of an array of cytokines and chemokines and (iii) links the innate and adaptive immune responses in vivo in a Toll-likereceptor-independent but MyD88-dependent manner. These data highlight the clinical utility of ISCOMATRIX adjuvant in the development of prophylactic and therapeutic vaccines for infectious disease.

show abstract

Section: Dose-sparing Benefits Of Iscomatrix Vaccinesmentioning

confidence: 60%

ISCOMATRIX: a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases

Morelli

Becher

Koernig

et al. 2012

Journal of Medical Microbiology

Self Cite

116

View full text Add to dashboard Cite

show abstract

“…Vaccines were tested at the antigen dose indicated, either alone or in formulation with either Iscomatrix adjuvant (60 g/dose) (18,19) or AlPO 4 .…”

Section: Methodsmentioning

confidence: 99%

Neuraminidase-Inhibiting Antibody Is a Correlate of Cross-Protection against Lethal H5N1 Influenza Virus in Ferrets Immunized with Seasonal Influenza Vaccine

Rockman

Brown

Barr

et al. 2013

J Virol

Self Cite

View full text Add to dashboard Cite

eIn preparing for the threat of a pandemic of avian H5N1 influenza virus, we need to consider the significant delay (4 to 6 months) necessary to produce a strain-matched vaccine. As some degree of cross-reactivity between seasonal influenza vaccines and H5N1 virus has been reported, this was further explored in the ferret model to determine the targets of protective immunity. Ferrets were vaccinated with two intramuscular inoculations of trivalent inactivated split influenza vaccine or subcomponent vaccines, with and without adjuvant, and later challenged with a lethal dose of A/Vietnam/1203/2004 (H5N1) influenza virus. We confirmed that vaccination with seasonal influenza vaccine afforded partial protection against lethal H5N1 challenge and showed that use of either AlPO 4 or Iscomatrix adjuvant with the vaccine resulted in complete protection against disease and death. The protection was due exclusively to the H1N1 vaccine component, and although the hemagglutinin contributed to protection, the dominant protective response was targeted toward the neuraminidase (NA) and correlated with sialic acid cleavage-inhibiting antibody titers. Purified heterologous NA formulated with Iscomatrix adjuvant was also protective. These results suggest that adjuvanted seasonal trivalent vaccine could be used as an interim measure to decrease morbidity and mortality from H5N1 prior to the availability of a specific vaccine. The data also highlight that an inducer of cross-protective immunity is the NA, a protein whose levels are not normally monitored in vaccines and whose capacity to induce immunity in recipients is not normally assessed.

show abstract

“…Subcutaneous injection of IS-COMATRIX®-adjuvanted 4 dengue virus envelope proteins (10 µg) resulted in adequate protection in both mouse and monkey challenge models [161]. Such an immune enhancement effect of ISCOMATRIX (50 µg) on recombinant HIV gp120 vaccine can be significantly greater than that aluminum hydroxide [162]. Similarly, immunization of patients with a mixture of HPV16 E6E7 fusion protein and ISCOMATRIX adjuvant induced antigen specific cell mediated immunity in terms of antibody formation, delayed type hypersensitivity, in vitro cytokine release, and CD8 T cell responses [163].…”

Section: Iscomatrixmentioning

confidence: 99%

Selection of Adjuvants for Enhanced Vaccine Potency

Wang¹,

Singh²

2011

WJV

View full text Add to dashboard Cite

show abstract

The utility of ISCOMATRIX™ adjuvant for dose reduction of antigen for vaccines requiring antibody responses

Cited by 43 publications

References 13 publications

ISCOMATRIX: a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases

ISCOMATRIX: a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases

Neuraminidase-Inhibiting Antibody Is a Correlate of Cross-Protection against Lethal H5N1 Influenza Virus in Ferrets Immunized with Seasonal Influenza Vaccine

Selection of Adjuvants for Enhanced Vaccine Potency

Contact Info

Product

Resources

About